Skip NavigationSkip to Content
Return Return to Search Results

Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus

  1. Author:
    Stergiopoulou, T.
    Meletiadis, J.
    Sein, T.
    Papaioannidou, P.
    Tsiouris, I.
    Roilides, E.
    Walsh, T. J.

  2. Author Address

    Stergiopoulou, Theodouli, Meletiadis, Joseph, Sein, Tin, Roilides, Emmanuel, Walsh, Thomas J.] NCI, Immunocompromised Host Sect, Paediat Oncol Branch, Bethesda, MD 20892 USA. [Stergiopoulou, Theodouli, Tsiouris, Ioannis, Roilides, Emmanuel] Aristotle Univ Thessaloniki, Hippokrat Hosp, Pediat Dept 3, GR-54006 Thessaloniki, Greece. [Meletiadis, Joseph] Univ Athens, Attiko Univ Hosp, Lab Clin Microbiol, Athens, Greece. [Sein, Tin] SAIC Frederick Inc, Frederick, MD 21702 USA. [Papaioannidou, Paraskevi] Aristotle Univ Thessaloniki, Fac Med, Dept Pharmacol, GR-54006 Thessaloniki, Greece.
    1. Year: 2009
    2. Date: Feb
  2. Journal: Journal of Antimicrobial Chemotherapy
    1. 63
    2. 2
    3. Pages: 343-348
  4. Type of Article: Article
  1. Abstract:

    Patients suffering from invasive mycoses often receive concomitant antifungal therapy and antibacterial agents. Ciprofloxacin, a carboxyfluoroquinolone, was previously observed to demonstrate the pharmacodynamic interactions with antifungal agents by altering their growth inhibitory activity against Candida albicans and Aspergillus fumigatus. However, little is known about the interaction between other extended-spectrum fluoroquinolones, such as levofloxacin and moxifloxacin, and antifungal agents against C. albicans and A. fumigatus. Using a microdilution chequerboard technique, we employed isobolographic analysis adapted to incorporate a non-active agent in order to analyse the potential in vitro interaction between ciprofloxacin, levofloxacin or moxifloxacin and the following representative antifungal agents: amphotericin B, fluconazole or voriconazole and caspofungin. Synergistic interactions [interaction indices (Iis) 0.69-0.83, P < 0.05] were observed between amphotericin B (0.07-0.31 mg/L) and either ciprofloxacin (0.19-7.65 mg/L) or levofloxacin (0.41-32.88 mg/L) against C. albicans and A. fumigatus. Synergy (Iis 0.56-0.87, P < 0.05) also was found between voriconazole (0.09-0.14 mg/L) and ciprofloxacin (0.22-11.41 mg/L) as well as between caspofungin (8.94-22.07 mg/L) and levofloxacin (0.14-5.17 mg/L) against A. fumigatus. Some antagonistic (Iis 1.16-1.29, P < 0.05) interactions were observed between fluoroquinolones and fluconazole against C. albicans. In general, ciprofloxacin enhanced the activity of antifungal agents more than moxifloxacin and levofloxacin against both C. albicans and A. fumigatus. The knowledge of the pharmacodynamic interactions between fluoroquinolones and antifungal agents may guide selection and potentially improve the outcome of immunosuppressed patients with concurrent bacterial and fungal infections.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/jac/dkn473
  3. PMID: 19109335
  4. PMCID: PMC2734084

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel